demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
breast cancer - HR positivebreast cancer - triple negative
la/mBC - HR-positive - 1st line (L1)la/mBC - HR positive - L1 - PIK3CA mutantmBC - Triple negative (TNBC) - 1st Line (L1)mBC - TNBC - L1 - all population
AKT inhibitor
capivasertib based treatment
capivasertib plus paclitaxel BEECH
ipatasertib based treatment
ipatasertib plus paclitaxel IPATunity130